Astonea LabsShare price, financial results, shareholding and management
- Market cap
- ₹431 cr
- Stock P/E
- 95.6peers 21.3
- Book value
- ₹55.2
- Price to book
- 7.43
- EV / operating profit
- -
- Market cap to sales
- 2.92
- ROCE · FY26
- 10.3%
- ROE · FY26
- 11.7%
- ROE, 3-year average
- 28.0%
- Operating margin · FY26
- 9.1%peers 10.2%
- Sales growth, 3 years
- 30.1%
- Profit growth, 3 years
- 65.2%
- Debt to equity
- 0.74peers 0.34
- Borrowings
- ₹43 cr
- Interest cover
- 2.7×
- Cash from business / op. profit
- -105%
- Debtor days
- 129
- Pledged
- 0.00%
- Promoter holding
- 72.30%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 376
- 52-week high / low
- ₹420 / ₹118
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Astonea Labs share price chart
Close on 19 Nov 2026 · 0.00% on the day · Vol 7,000
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +26.9%
- 3 months
- +47.0%
- 6 months
- +107.4%
- 1 year
- +188.5%
- Traded a day, 20 days
- ₹0.07 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +51% | -10% |
| 3 years, a year | +30% | +65% |
| Latest half, H2 FY26 | +62% | -4% |
About Astonea Labs: business, products and customers
Astonea Labs makes medicines and beauty products such as tablets, capsules, creams and toothpaste for other brands at its plant in Haryana, and sells a few products under its own names. Its shares trade on BSE SME.
The company was set up in 2017 and runs one plant at Raipur Rani in Panchkula district, Haryana, with separate lines for medicines (tablets, hard and soft capsules, sachets, ointments) and for cosmetics (lotions, gels, creams, oils, soaps, toothpaste). Most of its work is contract manufacturing for pharmaceutical and cosmetic companies across India, some of whom export the goods through merchant exporters. It also sells its own Glow Up skin and hair care range, launched in 2022 and sold on Amazon and Tata 1MG, and Regero medicines, launched in 2024.
The business model shapes the numbers. In contract manufacturing the company buys the raw material and packing, makes the product and charges the customer per order, so revenue includes the full material cost and margins depend on how full the lines are and what each order pays. Customers have no long-term contracts, and stock and money owed by customers tie up working capital that has been funded by bank loans and loans from a director's relatives.
Read more about the business
What is new: the company listed on BSE SME in June 2025 and planned to spend issue money on an ointment line for exports, product registration in Bolivia, brand building and working capital. In late 2025 the board proposed changing how the issue money is used, a stake of a third in Damaira Pharmaceuticals and investments abroad. The offer document names no listed rivals; it says many small and large makers offer similar products and compete on quality, price and reliability.
From the offer document (RHP) and the annual report for FY25 with its AGM notice of December 2025.
Read the deeper study ↓In its favour
- Sales have grown fast: 30% a year over three years.
- The promoters own a large part of the company: 72.30%.
To watch
- Shareholder approval of the proposed changes to how the issue money is used (AGM notice, Annual Report 2025, p.68 and p.82).
- Whether the ointment line for exports is bought and started (Offer document, p.95).
- The proposed stake of a third in Damaira Pharmaceuticals (Annual Report 2025, p.67).
- Loans from a director's relatives and the new board members appointed in November 2025 (Annual Report 2025, p.16 and p.19).
- It paid no dividend in the past year.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Astonea Labs revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit fell even as sales rose, so the company kept less from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.
Astonea Labs half-yearly results
SME companies report every six months · ₹ crore
| H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|
| Sales | 47 | 50.25 | 66.29 | 81.29 |
| Expenses | 41 | 41.71 | 60.92 | 73.31 |
| Operating profit | 7 | 8.54 | 5.37 | 7.99 |
| OPM | 14.0% | 17.0% | 8.1% | 9.8% |
| Interest | 2 | 1.91 | 1.54 | 1.72 |
| Depreciation | 2 | 2.46 | 2.15 | 2.84 |
| Profit before tax | 3 | 4.28 | 1.77 | 3.85 |
| Net profit | 2 | 3.22 | 1.42 | 3.10 |
Astonea Labs profit and loss
Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Sales | 30 | 67 | 80 | 98 | 147.58 |
| Expenses | 24 | 60 | 68 | 82 | 134.23 |
| Operating profit | 6 | 7 | 12 | 15 | 13.35 |
| OPM | 19.0% | 11.0% | 15.0% | 16.0% | 9.1% |
| Other income | 0 | 0 | 0 | 0 | 0.52 |
| Interest | 2 | 2 | 3 | 4 | 3.26 |
| Depreciation | 4 | 4 | 4 | 5 | 4.99 |
| Exceptional and other items | 1 | · | · | 1 | · |
| Profit before tax | 1 | 1 | 5 | 7 | 5.62 |
| Tax rate | 100.0% | 0.0% | 20.0% | 28.6% | 19.8% |
| Net profit | 0 | 1 | 4 | 5 | 4.51 |
| EPS ₹ | 0.62 | 1.68 | 5.36 | 6.93 | 4.49 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY25 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
A tax rate above 60% or below zero (FY22) comes from tax charged on a small or negative profit, as reported.
Astonea Labs profitability
Margins and returns on capitalLast year the company kept less from each rupee of sales than the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Operating margin | 19.0% | 11.0% | 15.0% | 16.0% | 9.1% |
| Tax rate | 100.0% | 0.0% | 20.0% | 28.6% | 19.8% |
| ROCE | · | 7.4% | 16.3% | 17.5% | 10.3% |
| ROE | · | 13.3% | 40.0% | 32.3% | 11.7% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Astonea Labs debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Astonea Labs balance sheet
At each 31 March · ₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 8 | 8 | 11 |
| Reserves | 3 | 4 | 4 | 11 | 47 |
| Net worth | 7 | 8 | 12 | 19 | 58 |
| Borrowings | 30 | 36 | 42 | 53 | 43 |
| Other liabilities | 16 | 20 | 27 | 31 | 45 |
| Total liabilities | 53 | 64 | 81 | 103 | 146 |
| Fixed assets | 21 | 21 | 22 | 26 | 31 |
| Capital work in progress | 0 | 0 | 2 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| Other assets | 32 | 43 | 57 | 73 | 101 |
Astonea Labs cash flow
₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | -5 | -1 | 8 | 9 | -14 |
| Cash from investing | -3 | -3 | -8 | -11 | -20 |
| Cash from financing | 8 | 4 | 0 | 2 | 34 |
| Net cash flow | 0 | 0 | 0 | 0 | 0 |
Working capital
Days
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Debtor days | 235 | 104 | 116 | 142 | 129 |
| Inventory days | 136 | 121 | 161 | 161 | 125 |
| Days payable | 273 | 128 | 149 | 144 | 150 |
| Cash conversion cycle | 98 | 97 | 128 | 159 | 103 |
| Working capital days | 98 | 33 | 28 | 22 | 74 |
Astonea Labs peers and competitors
Listed SME companies in the same industryBy sales, Astonea Labs is number 7 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 431 | 95.6 | 148 | 4.5 | 9.1% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Median of the 10 others | 111 | 21.3 | 130 | 9.3 | 10.2% | 0.34 |
Astonea Labs shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders has come down.
Astonea Labs shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Jun 25 | Sep 25 | Mar 26 | |
|---|---|---|---|
| Promoters | 72.30% | 72.30% | 72.30% |
| Foreign investors (FIIs) | 8.01% | 2.51% | - |
| Indian institutions (DIIs) | 4.55% | 0.35% | - |
| Number of shareholders | 1,014 | 437 | 376 |
Astonea Labs study: the business from its own documents
Read from 4 of the company's own documentsAstonea Labs key facts from the filings
Each figure with the document it comes from
- Contract manufacturing
- 90.31%
- Share of revenue from making products for other companies in April to December 2024; own brands gave 9.69%.Offer document, p.39
- Exports
- 1.62%
- Share of revenue from direct exports in April to December 2024; nearly all the rest was for Indian customers.Offer document, p.39
- Top five customers
- 30.64%
- Share of revenue in April to December 2024, down from 61.26% in FY23 as the customer base widened.Offer document, p.147
- Tablet line use
- 77%
- Tablet and hard capsule lines were 77% used at December 2024; soft capsules were at 30% and sachets at 5%.Offer document, p.150
- Cosmetics line use
- 50% to 80%
- Lotions, gels, creams and toothpaste ran at 50% to 80% at December 2024; oils were at 10%.Offer document, p.151
Show 5 more facts
- FY25 revenue
- ₹97.5 cr
- Revenue from operations in FY25, up from ₹80.2 cr in FY24.Annual Report 2025, p.14
- FY25 profit
- ₹5.4 cr
- Profit after tax in FY25, up from ₹4.1 cr in FY24.Annual Report 2025, p.14
- Loans from relatives
- ₹5.5 cr
- Unsecured loans from relatives of a director during FY25, beside ₹0.05 cr from Ashish Gulati.Annual Report 2025, p.19
- Ointment line for exports
- ₹5.2 cr
- Issue money set aside for new ointment machinery on the plant's second floor; the board later proposed changes to how issue money is used.Offer document, p.95; Annual Report 2025, p.68
- Employees
- 217
- People on the payroll at the time of the offer document, 67 of them in field sales.Offer document, p.152
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company has not given guidance on sales or profit. Its plan in the offer document was to spend issue money in FY25 and FY26 on an ointment line for exports, product registration in Bolivia, advertising and working capital. The AGM notice of December 2025 asks shareholders to approve changes to that use of money, a stake of a third in Damaira Pharmaceuticals and investments in companies abroad.
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
The company earns its money by making medicines and beauty products to order for other brands, using one plant that holds both drug and cosmetic approvals.
Its weak spots are thin margins on order-by-order work, a lot of money tied up in stock and money owed, and frequent changes in officers and in plans for the issue money.
WatchCan it set its own prices?No. Brand owners can move orders to many other contract makers, so prices are agreed order by order.
AverageHow strong is it against rivals?Making both medicines and cosmetics under one roof, with WHO-GMP and ISO approvals, is useful to customers, but many makers offer similar products.
AverageWho are its customers?Unnamed Indian pharma and cosmetic companies with no long-term contracts, though reliance on the biggest buyers has fallen.
WatchDoes it need a lot of money?Yes. Raw material, stock and money owed by customers need working capital, and the plant needs regular spending.
AverageCan it keep finding new work?Several lines have room to make more, and a wider customer list helps, but there is no order book and exports are small.
AverageDo good and bad years swing a lot?Demand for medicines and personal care is steady, but margins have moved a lot with order mix and raw material prices.
Who runs Astonea Labs?
Promoters, directors and officers; tap a name for the background
AGAshish GulatiPromoter and Managing Director
BSc in Motorsport Technology from Oxford Brookes University, United Kingdom (2013); earlier sales director at Shinto Organics for about a year (2016 to 2017). With the company since incorporation, leading quality, production, marketing and regulatory teams; Managing Director again from April 2022 for five years.
Offer document, p.171 and p.173PSPooja SinghExecutive Director
Bachelor of Pharmacy from Dr. A.P.J. Abdul Kalam Technical University (2015) with over eight years in quality assurance, starting at Mediwell Healthcare; joined as Executive QA in August 2021 and a director since March 2024.
Offer document, p.172VVikrantDirector, proposed as Executive Director
Appointed an additional non-executive director on 10 November 2025; the board proposed regularising the appointment and making it executive. The documents give no further background.
Annual Report 2025, p.16 and p.84KVKaran Vir BindraIndependent Director
Law graduate from Panjab University (2012) and a fellow of the Institute of Company Secretaries of India, in practice at KV Bindra & Associates with over 10 years in governance and compliance.
Offer document, p.172AAAkash AroraIndependent Director
B.Com from S.D. College, Muzaffarnagar and a chartered accountant (2013); earlier senior manager at HDFC Bank (2016 to 2019) and at Hero FinCorp.
Offer document, p.172Astonea Labs latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹81.3 cr (+62%), net profit ₹3.1 cr (-4%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 72.30%.
Astonea Labs announcements
8 on record, latest first; each opens the filing on the exchange
- Company UpdatePlease find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the ObjecPDF ↗
- Company UpdateIntimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private LimitedPDF ↗
- Company UpdatePlease find enclosed herewith the Certificate under Reg. 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, pertaining to the quarter ended 30PDF ↗
- ResultPlease find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025PDF ↗
- ResultPlease find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a partPDF ↗
- Insider Trading / SASTThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish GulatiPDF ↗
- Company UpdatePlease find enclosed herewith disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulation, 2015 as received from Mr. Ashish Gulati,PDF ↗
- Company UpdatePlease find enclosed herewith disclosure as per Regulation 29(1) of SEBI (Substantial Acquisition of shares & Takeovers) Regulation, 2011 as received from Mr. APDF ↗
Astonea Labs annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
Astonea Labs share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Astonea Labs' data · 8
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,05,11,000 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY22 to FY26.
- iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.
Questions people ask about Astonea Labs
What does Astonea Labs do?
Astonea Labs makes medicines and beauty products such as tablets, capsules, creams and toothpaste for other brands at its plant in Haryana, and sells a few products under its own names. Its shares trade on BSE SME.
What is the share price of Astonea Labs?
₹410 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Astonea Labs?
₹431 cr at the close on 19 Nov 2026, on 1,05,11,000 shares.
What is the P/E of Astonea Labs?
95.6 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Astonea Labs' revenue and profit?
Revenue ₹148 cr and profit after tax ₹5 cr in FY26.
Who are the promoters of Astonea Labs?
Ashish Gulati; promoters held 72.30% at 31 March 2026.
What is Astonea Labs' website?
www.astonea.org
More SME companies like Astonea Labs
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Infinium PharmachemINFINIUM · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹464 cr
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹476 cr
- Trident LifelineTLL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹490 cr
- Influx HealthtechINFLUX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹644 cr
- Accretion NutravedaANL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹244 cr
- Accretion PharmaceuticalsACCPL · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹227 cr
Every listed SME company in Pharmaceuticals & Biotechnology →
Built from 2 annual reports, 1 offer document, 1 result filing, 8 exchange announcements, 3 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.